Loading...

Purified anti-human CD16 Antibody

Pricing & Availability
Clone
3G8 (See other available formats)
Regulatory Status
RUO
Workshop
V NK80
Other Names
FcγRIII, Fc gamma receptor, Fc gamma receptor 3
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
3G8_Pure_071805
Human peripheral blood lymphocytes stained with purified 3G8 and anti-mouse IgGs FITC
  • 3G8_Pure_071805
    Human peripheral blood lymphocytes stained with purified 3G8 and anti-mouse IgGs FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
302001 25 µg 52€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302002 100 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Capuchin Monkey, Chimpanzee, Common Marmoset, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human PMN cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/mL
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF® - Verified
Block, IHC-F, IP, Stim - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The 3G8 antibody clone blocks neutrophil phagocytosis and stimulates NK cell proliferation. It has been reported that this clone interacts with the FcγRIIa and FcγRIIIb receptors causing neutrophil activation and aggregation18. Due to this phenomenon staining in whole blood may cause a reduction in the number of granulocytes or alter their scatter profile.

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections6, immunoprecipitation3, stimulation of NK cell proliferation4, blocking of phagocytosis5, and blocking of immunoglobulin binding to FcγRIII7,8. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302049, 302050, 302057, 302058).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP)
  4. Hoshino S, et al. 1991. Blood 78:3232. (Stim)
  5. Tamm A, et al. 1996. Immunol. 157:1576. (Block)
  6. Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC)
  7. Holl V, et al. 2004. J. Immunol. 173:6274. (Block)
  8. Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block)
  9. Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed
  10. Smed-Sörensen A, et al. 2008. Blood 111:5037. (Block) PubMed
  11. Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  14. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  15. Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed
  16. Wu Z, et al. 2013. J. Virol. 87:7717. PubMed
  17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  18. Vossebeld PJ, et al. 1997. Biochem J. 323:87-94 (Stim)
Product Citations
  1. Dorsch M, et al. 2020. Eur J Immunol. 50:656. PubMed
  2. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  3. McCarthy EE, et al. 2022. Cell Rep. 39:110815. PubMed
  4. Shemesh A, et al. 2022. J Exp Med. 219: . PubMed
  5. Kirolos SA, et al. 2022. J Leukoc Biol. 112:1399. PubMed
  6. Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed
  7. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  8. Miyamoto DT, et al. 2018. Cancer Discov. 0.533333333. PubMed
  9. Korn MA, et al. 2020. J Immunol. 205:2595. PubMed
  10. Friedman D, et al. 2021. J Cell Sci. 134:. PubMed
  11. Wu Z, et al. 2013. J Virol. 87:7717. PubMed
  12. Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed
  13. Holder KA, et al. 2021. Clin Transl Immunology. 10:e1348. PubMed
  14. Smed-Sörensen A, et al. 2008. Blood. 111:5037. PubMed
  15. Cao Q, et al. 2018. Am J Physiol Renal Physiol. 314:F561. PubMed
  16. Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed
  17. Mask E, et al. 2022. Front Cell Infect Microbiol. 12:880860. PubMed
  18. Santos R, et al. 2017. Nat Commun. . 10.1038/s41467-017-01760-5. PubMed
  19. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  20. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  21. Boltz A, et al. 2011. J Biol Chem. 286:21896. PubMed
  22. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  23. Li L, et al. 2019. Cell Stem Cell. 24:271. PubMed
  24. Gainers M, et al. 2007. J Immunol. 179:8509. PubMed
  25. Sibener LV et al. 2018. Cell. 174(3):672-687 . PubMed
  26. Syrimi E, et al. 2021. iScience. 24:103215. PubMed
  27. Okubo K, et al. 2021. Cell Reports. 35(7):109142. PubMed
  28. Urlaub D, et al. 2017. J Immunol. 198:1944. PubMed
  29. Jog NR, et al. 2018. Front Immunol. 9:2198. PubMed
  30. Eldredge LC, et al. 2019. Am J Physiol Lung Cell Mol Physiol. 317:L49. PubMed
  31. Olin A, et al. 2018. Cell. 174:1277. PubMed
  32. Farhadian SF, et al. 2022. JCI Insight. 7:. PubMed
  33. Park YJ, et al. 2022. PLoS Pathog. 18:e1010468. PubMed
  34. Park JE, et al. 2020. Journal for ImmunoTherapy of Cancer. 8(2):e000873.. PubMed
  35. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  36. Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed
  37. Prodjinotho UF, et al. 2017. PLoS Negl Trop Dis. 11:e0005777. PubMed
  38. Ehinger E, et al. 2021. Cardiovasc Res. 117:1166. PubMed
  39. Frobel J, et al. 2018. Clin Epigenetics. 10:67. PubMed
  40. Li J, et al. 2021. Haematologica. 106:3115. PubMed
  41. Shemesh A, et al. 2022. J Exp Med. 219:. PubMed
  42. Kato M, et al. 2021. PLoS One. 16:e0252116. PubMed
  43. Combes AJ, et al. 2021. Nature. 591:124. PubMed
  44. Mody P, et al. 2007. Blood. 110:2974. PubMed
  45. Ardain A, et al. 2019. Nature. 570:528. PubMed
  46. Doni A, et al. 2021. Nat Commun. 12:3739. PubMed
  47. Steffen U, et al. 2020. Nat Commun. 0.541666667. PubMed
  48. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  49. Pohl K, et al. 2018. PLoS One. 13:e0209026. PubMed
  50. Farrington LA, et al. 2020. PLoS Pathog. 16:e1008997. PubMed
  51. De Maeyer RPH, et al. 2020. Nat Immunol. 21:615. PubMed
  52. Ravindran A, et al. 2018. Front Immunol. 9:2193. PubMed
  53. Edri-Brami M, et al. 2012. PLoS One. 7:e35772. PubMed
  54. Lakshmikanth T, et al. 2020. Cell Reports. 32(3):107923. PubMed
  55. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  56. Sung JA, et al. 2018. Mol Ther. 26:2496. PubMed
  57. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
  58. Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed
  59. Zhong Q, et al. 2018. J Immunol. 200:3913. PubMed
  60. Martin E, et al. 2020. JCI Insight. :5. PubMed
  61. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
  62. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
RRID
AB_314202 (BioLegend Cat. No. 302001)
AB_314202 (BioLegend Cat. No. 302002)

Antigen Details

Structure
Ig superfamily, transmembrane form (50-65 kD) or GPI-linked form (48 kD)
Distribution

NK cells, activated monocytes, macrophages, neutrophils

Function
Low affinity IgG Fc receptor, phagocytosis, ADCC
Ligand/Receptor
Aggregated IgG, IgG-antigen complex
Cell Type
Dendritic cells, Macrophages, Monocytes, Neutrophils, NK cells
Biology Area
Immunology, Innate Immunity
Molecular Family
CD Molecules, Fc Receptors
Antigen References

1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275.
2. Stroncek D, et al. 1991. Blood 77:1572.
3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.

Gene ID
2214 View all products for this Gene ID
UniProt
View information about CD16 on UniProt.org

Related FAQs

Is our human Trustain FcX™ (cat# 422302) compatible with anti human CD16, CD32 and CD64 clones 3G8, FUN-2 and 10.1 respectively?

Yes

Other Formats

View All CD16 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD16 3G8 FC
Biotin anti-human CD16 3G8 FC
FITC anti-human CD16 3G8 FC
Brilliant Violet 711™ anti-human CD16 3G8 FC
PE anti-human CD16 3G8 FC
PE/Cyanine5 anti-human CD16 3G8 FC
Purified anti-human CD16 3G8 FC,CyTOF®,Block,IHC-F,IP,Stim
APC/Cyanine7 anti-human CD16 3G8 FC
PE/Cyanine7 anti-human CD16 3G8 FC
Alexa Fluor® 488 anti-human CD16 3G8 FC
Alexa Fluor® 647 anti-human CD16 3G8 FC
Pacific Blue™ anti-human CD16 3G8 FC
Alexa Fluor® 700 anti-human CD16 3G8 FC
PerCP/Cyanine5.5 anti-human CD16 3G8 FC
PerCP anti-human CD16 3G8 FC
Brilliant Violet 421™ anti-human CD16 3G8 FC
Brilliant Violet 570™ anti-human CD16 3G8 FC
Brilliant Violet 605™ anti-human CD16 3G8 FC
Brilliant Violet 650™ anti-human CD16 3G8 FC
Brilliant Violet 785™ anti-human CD16 3G8 FC
Brilliant Violet 510™ anti-human CD16 3G8 FC
Ultra-LEAF™ Purified anti-human CD16 3G8 FC,CyTOF®,Block,IHC-F,IP,Stim
Purified anti-human CD16 (Maxpar® Ready) 3G8 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD16 3G8 FC
APC/Fire™ 750 anti-human CD16 3G8 FC
PE anti-human CD16 3G8 FC
APC anti-human CD16 3G8 FC
Pacific Blue™ anti-human CD16 3G8 FC
PE/Dazzle™ 594 anti-human CD16 3G8 FC
TotalSeq™-A0083 anti-human CD16 3G8 PG
TotalSeq™-B0083 anti-human CD16 3G8 PG
TotalSeq™-C0083 anti-human CD16 3G8 PG
PE/Cyanine7 anti-human CD16 3G8 FC
PE/Fire™ 640 anti-human CD16 3G8 FC
FITC anti-human CD16 3G8 FC
Spark YG™ 581 anti-human CD16 3G8 FC
APC/Fire™ 750 anti-human CD16 3G8 FC
TotalSeq™-D0083 anti-human CD16 3G8 PG
APC/Fire™ 810 anti-human CD16 3G8 FC
GMP APC anti-human CD16 3G8 FC
GMP PE/Dazzle™ 594 anti-human CD16 3G8 FC
GMP PE anti-human CD16 3G8 FC
Spark Red™ 718 anti-human CD16 3G8 FC
GMP Pacific Blue™ anti-human CD16 3G8 FC
GMP FITC anti-human CD16 3G8 FC
Spark Blue™ 515 anti-human CD16 3G8 FC
Spark UV™ 387 anti-human CD16 3G8 FC
PerCP/Cyanine5.5 anti-human CD16 3G8 FC
GMP PE/Cyanine7 anti-human CD16 3G8 FC
GMP APC/Fire™ 750 anti-human CD16 3G8 FC
Brilliant Violet 750™ anti-human CD16 3G8 FC
Spark Blue™ 550 anti-human CD16 3G8 FC
GMP PerCP/Cyanine5.5 anti-human CD16 3G8 FC
Spark YG™ 593 anti-human CD16 3G8 FC
Spark NIR™ 685 anti-human CD16 3G8 FC
Spark Violet™ 500 anti-human CD16 3G8 FC
Spark Blue™ 574 anti-human CD16 (Flexi-Fluor™) 3G8 FC
Spark PLUS UV395™ anti-human CD16 3G8 FC
Go To Top Version: 4    Revision Date: 08/22/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account